Tempus AI Receives FDA Clearance for AI-Powered ECG Software to Detect Mitral Regurgitation
Tempus AI, Inc. has announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new artificial intelligence (AI) product, Tempus ECG-MR. This software is designed to analyze standard 12-lead resting electrocardiograms (ECGs) to identify signs associated with undiagnosed moderate or severe mitral regurgitation (MR). Mitral regurgitation is a common heart valve condition where blood leaks backward through the mitral valve. Early stages of MR often present without symptoms or with non-specific symptoms, leading to potential delays in diagnosis. The Tempus ECG-MR aims to help identify patients at higher risk of moderate or severe MR who may require further evaluation, including diagnostic imaging. The software is intended for use on clinical diagnostic ECG recordings collected at healthcare facilities from patients aged 65 years or older who are at risk of cardiovascular disease. This includes individuals with conditions such as coronary artery disease, hypertension, obesity...
